AECOPD
Conditions
Interventions
Experimental group 1:XCBQT+Budesonide Suspension for inhalation (2)
Experimental group 2:XCBQT+Budesonide Suspension for inhalation (1ml)
control group:XCBQT placebo+Budesonide Suspension for inhalation (2ml)
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria of COPD; 2. The clinical grade of severity of COPD was I-II; 3. The patient has indications for antibiotic treatment(Consensus of Chinese experts on diagnosis and treatment of AECOPD (revised edition 2017)); 4. Diagnosed with Phlegm-Heat Excess Syndrome; 5. Aged 40 to 80 years old; 6. Those who signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. patients with asthma, bronchiectasis, pulmonary cystic fibrosis, pulmonary fibrosis, lung cancer or other known causes and airflow limitation diseases with characteristic pathological manifestations; 2. patients with coronary heart disease, hypertensive heart disease, cardiac valve diseases and other diseases that cause labor force shortness; 3. having indications for the application of invasive mechanical ventilation; 4. patients with high clinical suspicion or diagnosis of pulmonary embolism; 5. patients with serious primary diseases of cardio-cerebrovascular, hepatic and renal hematopoietic system and endocrine system; 6. patients with intestinal obstruction requiring surgical intervention; 7. Pregnant and lactating women; 8. Mental retardation, mental retardation; 9. Liver and kidney function Scr>1.0ULN, ALT(AST) >1.5ULN; 10. People who need a combination of immunosuppressive agents; 11. Those who have used oral antibiotics for more than 3 days before screening or who have used antibiotics intravenously; 12. those who are known to be allergic to the basic therapeutic drugs; 13. those who are known to be allergic to the pharmaceutical ingredients prescribed by Chinese medicine; 14. those who have participated in or are participating in other clinical trials within the last 3 months; 15. the researcher thinks that it is inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical symptoms;clinical symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| capacity for action (mMRC);blood gas analysis;Serum inflammatory markers;Serum inflammatory markers;hospital stays;Theoretical discharge time;death rate;The proportion of patients with invasive mechanical ventilation;Proportion of patients admitted to ICU;Readmission rate within 30 days after discharge;TCM score;Clinical evaluation of TCM syndrome; | — |
Countries
China
Contacts
Public ContactZhang Hongchun
China-Japan Friendship Hospital
Outcome results
None listed